GLP1R and familial dilated cardiomyopathy: These findings suggest that GLP-1 receptor activation could attenuate high glucose-induced cardiomyocyte apoptosis by mechanisms involving reduced ER stress and by improved SERCA2a activity, which further boosts the use of GLP-1 receptor-based therapies as treatments for DCM [43,132,133].